Elcys

ELCYS ® is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN); and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. It can also be added to amino acid solutions to provide a more complete profile of amino acids for protein synthesis. ELCYS ® is a sulfur-containing amino acid indicated to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN); and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN.

It can also be added to amino acid solutions to provide a more complete profile of amino acids for protein synthesis. ( 1 )

ELCYS ® is contraindicated in:

• Patients with known hypersensitivity to one or more amino acids.
• Patients with inborn errors of amino acid metabolism due to risk of severe metabolic or neurologic complications.
• Patients with pulmonary edema or acidosis due to low cardiac output.
• Hypersensitivity to one or more amino acids ( 4 )
• Inborn errors of amino acid metabolism ( 4 )
• Pulmonary edema or acidosis due to low cardiac output ( 4 )

• Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. ( 5.1 )
• Vein Damage and Thrombosis: Solutions with osmolarity of 900 mOsm/L or more must be infused through a central catheter. ( 2.1 , 5.2 )
• Increased blood urea nitrogen (BUN): Monitor laboratory parameters and discontinue if exceeds normal postprandial limits and continues to increase. ( 5.3 )
• Acid-Base Imbalance: Monitor laboratory parameters and supplement with electrolytes as needed. ( 5.4 )
• Hepatobiliary Disorders: Monitor liver function parameters and ammonia levels. ( 5.5 )
• Hyperammonemia: Neurocognitive delay possible in infants; monitor blood ammonia levels. ( 5.6 , 8.4 )
• Aluminium Toxicity: Increased risk in patients with renal impairment, including preterm infants. ( 5.7 , 8.4 )
• Monitoring and Laboratory Tests: Monitor fluid and electrolytes, serum osmolarity, blood glucose, kidney and liver function, blood count and coagulation parameters throughout treatment. ( 5.8 )